MMP-2 (タンパク質 | 抗体 | cDNA クローン | ELISA キット)

All MMP-2 reagents are produced in house and quality controlled, including 7 MMP-2 Antibody, 13 MMP-2 Gene, 1 MMP-2 IP Kit, 2 MMP-2 Lysate, 2 MMP-2 Protein, 1 MMP-2 qPCR. All MMP-2 reagents are ready to use.

MMP-2 Protein (2)

MMP-2 Antibody (7)

MMP-2 cDNA Clone (13)

NM_004530.4

クローニングベクター cDNA 製品

In lentiviral vector

MMP-2 qPCR Primer (1)

MMP-2 Lysate (2)

MMP-2 の背景知識

Matrix Metalloproteinase-2 (MMP-2) is an enzyme that degrades components of the extracellular matrix and thus plays a pivotal role in cell migration during physiological and pathological processes. MMP-2 expression is dependent on extracellular matrix metalloproteinase inducer (EMMPRIN), Her2/neu, growth factors, cytokines, and hormones. Pro-MMP-2 activation needs MT1-MMP and TIMP-2 contribution. MMP-2 is changed in distribution and increased in amount in the ventral cochlear nucleus after unilateral cochlear ablation. A low level of MMP-2 is linked to favorable prognosis in patients with a hormone receptor-negative tumor, usually associated with high risk. As a zymogen requiring proteolytic activation for catalytic activity, MMP-2 has been implicated broadly in the invasion and metastasis of many cancer model systems, including human breast cancer (HBC). Blocking MMP-2 secretion and activation during breast carcinoma development may decrease metastasis. The detection of active MMP-2 alone or the rate of pro-MMP-2 and active MMP-2 is considered a very sensitive indicator of cancer metastasis. Modulation of MMP-2 expression and activation through specific inhibitors and activators may thus provide a new mechanism for breast cancer treatment.

MMP-2 の参考文献

  • Thompson EW, et al. (1994) Collagen induced MMP-2 activation in human breast cancer. Breast Cancer Res Treat. 31(2-3): 357-70.
  • Jezierska A, et al. (2009) Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 15(2): RA32-40.
  • Fredrich M, et al. (2010) MMP-2 is involved in synaptic remodeling after cochlear lesion. Neuroreport. 21(5): 324-7.